Answers are grounded in this paper and cite their sources.
Evaluates seizure outcomes after switching from valproate to alternative medications, indicating risks involved.
Objective: To evaluate seizure control in women of reproductive age treated with valproic acid and to compare seizure outcomes between those who continued valproic acid and those who were switched to other antiseizure medications. Methods: Data of women with epilepsy were analyzed from prospectively maintained electronic medical records between 2013 and 2022 at a tertiary epilepsy referral center. Women aged 18 to 45 years with generalized or focal epilepsy who were well-controlled on valproic acid were included. Clinical characteristics, antiseizure medication use, seizure control during valproic acid treatment and after switching to other antiseizure medications, adverse effects, and pregnancy-related complications were analyzed. Results: Sixty-nine women with epilepsy who were seizure-free for at least 1 year on valproic acid were included. Of these, 28 had juvenile myoclonic epilepsy, 30 had other idiopathic generalized epilepsy subtypes, and 11 had focal epilepsy. Only 26 patients (37.68%) required a valproic acid dose greater than 800 mg/day for seizure control. Eighteen patients were switched from valproic acid to other antiseizure medications, of whom 10 (55.55%) experienced seizure recurrence at 12-month follow-up. Among patients who continued valproic acid, teratogenicity occurred in three patients (5.88%), with a mean daily dose of 1133 mg. The requirement for polytherapy was higher in the switch group compared to the valproic acid continuation group (44.44% vs. 11.8%). Significance: In women with epilepsy who are well-controlled on low-dose valproic acid, switching to alternative antiseizure medications is associated with a high risk of seizure recurrence and increased need for polytherapy. Decisions regarding withdrawal of valproic acid should be individualized, planned well in advance of pregnancy, and made after detailed discussion with the patient, balancing the risks of seizure worsening against potential teratogenic effects. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
No takes yet. Share an insight, caveat, or question.
Sridhar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: